Peptidomimetics as Inhibitors
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 3 707
Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi,
P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.;
Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.;
Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.;
Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent,
selective, and orally, bioavailable inhibitor of hepatitis C virus NS3-
4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899–
909.
27.1, 26.9, 26.4, 26.3, 24.2, 23.8, 22.6, 18.9, 15.7, 13.0 ppm. HRMS
(FAB) calcd for C39H61N6O8 [M + H]+: 741.4551, found 741.4543.
Supporting Information Available: Spectroscopical data for
macrocyclic compounds 18-23, L-serine derived macrocycles
24-32, and allo-threonine derived macrocycles 33-35. This
material is available free of charge via the Internet at http://
pubs.acs.org.
(12) (a) Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.;
Bonneau, P.; Bo¨s, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.;
Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace´, L.;
LaPlante, S. R.; Narjes, H.; Poupart, M-A.; Rancourt, J.; Sentjens, R. E.;
George, T. S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos,
Y. S.; Weldon, S. M.; Yong, C.-L.; Llina`s-Brunet, M. An NS3 protease
inhibitor with antiviral effects in humans infected with hepatitis C virus.
Nature 2003, 426, 186–189. (b) Llinas-Brunet, M.; Bailey, M. D.;
Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.;
Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette,
N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D.
Structure-activity study on a novel series of macrocyclic inhibitors of
the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
J. Med. Chem. 2004, 47, 1605–1608.
(13) For recent examples, see the following: (a) Grieco, P.; Cai, M.; Liu,
L.; Mayorov, A.; Chandler, K.; Trivedi, D.; Lin, G.; Campiglia, P.;
Novellino, E.; Hruby, V. J. Design and microwave-assisted synthesis
of novel macrocyclic peptides active at melanocortin receptors:
discovery of potent and selective hMC5R receptor antagonists. J. Med.
Chem. 2008, 51, 2701–2707. (b) Marsault, E.; Hoveyda, H. R.;
Peterson, M. L.; Saint-Louis, C.; Landry, A.; Ve´zina, M.; Ouellet, L.;
Wang, Z.; Ramaseshan, M.; Beaubien, S.; Benakli, K.; Beauchemin,
S.; De´ziel, R.; Peeters, T.; Fraser, G. L. Discovery of a new class of
macrocyclic antagonists to the human motilin receptor. J. Med. Chem.
2006, 49, 7190–7197. For reviews, see the following: (c) Li, P.; Roller,
P. P. Cyclization strategies in peptide derived drug design. Curr. Top.
Med. Chem. 2002, 2, 325–341. (d) Li, P.; Roller, P. P.; Xu, J. Current
synthetic approaches to peptide and peptidomimetic cyclization. Curr.
Org. Chem. 2002, 6, 411–440.
(14) (a) Venkatraman, S.; Njoroge, F. G.; Girijavallabhan, V. M.; Madison,
V.; Yao, N. H.; Prongay, A. J.; Butkiewicz, N.; Pichardo, J. Design
and synthesis of depeptidized macrocyclic inhibitors of hepatitis C
NS3-4A protease using structure-based drug design. J. Med. Chem.
2005, 48, 5088–5091. (b) Chen, K. X.; Njoroge, F. G.; Vibulbhan,
B.; Prongay, A.; Pichardo, J.; Madison, V.; Buevich, A.; Chan, T.-M.
Proline-based macrocyclic inhibitors of the hepatitis C virus: stereo-
selective synthesis and biological activity. Angew. Chem., Int. Ed. 2005,
44, 7024–7028. (c) Chen, K. X.; Njoroge, F. G.; Arasappan, A.;
Venkatraman, S.; Vibulbhan, B.; Yang, W.; Parekh, T. N.; Pichardo,
J.; Prongay, A.; Cheng, K.-C.; Butkiewicz, N.; Yao, N.; Madison, V.;
Girijavallabhan, V. Novel potent hepatitis C virus NS3 serine protease
inhibitors derived from proline-based macrocycles. J. Med. Chem.
2006, 49, 995–1005. (d) Arasappan, A.; Njoroge, F. G.; Chen, K. X.;
Venkatraman, S.; Parekh, T. N.; Gu, H.; Pichardo, J.; Butkiewicz,
N.; Prongay, A.; Madison, V.; Girijavallabhan, V. P2-P4 macrocyclic
inhibitors of hepatitis C virus NS3-4A serine protease. Bioorg. Med.
Chem. Lett. 2006, 16, 3960–3965.
(15) Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-
T.; Lovey, R. G.; Venkatraman, S.; Pan, W.; Parekh, T.; Pike, R. E.;
Ruan, S.; Liu, R.; Baroudy, B.; Agrawal, S.; Chase, R.; Ingravallo,
P.; Pichardo, J.; Prongay, A.; Brisson, J.-M.; Hsieh, T. Y.; Cheng,
K.-C.; Kemp, S. J.; Levy, O. E.; Lim-Wilby, M.; Tamura, S. Y.;
Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Discovery of SCH
446211 (SCH 6): a new ketoamide inhibitor of the HCV NS3 serine
protease and HCV subgenomic RNA replication. J. Med. Chem. 2006,
49, 2750–2757.
References
(1) (a) Hepatitis C. Fact Sheet No. 164; World Health Organization
(WHO): Geneva, Switzerland, Revised October 2000. WHO Web site:
Alter, M. J. Epidemiology of hepatitis C: geographic differences and
temporal trends. Semin. LiVer Dis. 2000, 20, 1–16. (c) Brown, R. S.
Jr; Gaglio, P. J. Scope of worldwide hepatitis C problem. LiVer
Transplant. 2003, 9, S10–S13.
(2) Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl.
J. Med. 2001, 345, 41–52.
(3) (a) McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.;
Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M-H.; Cort, S.;
Albrecht, J. K. Interferon alfa-2b alone or in combination with ribavirin
as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998,
339, 1485–1492. (b) Fried, M. W.; Shiffman, M. L.; Reddy, K. R.;
Smith, C.; Marinos, G.; Gonc¸ales, F. L., Jr.; Ha¨ussinger, D.; Diago,
M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu,
J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus
infection. N. Engl. J. Med. 2002, 347, 975–982.
(4) Poynard, T.; Marcellin, P.; Lee, S. S.; Niederau, C.; Minuk, G. S.;
Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem, S.; Trepo, C.; Albrecht, J.
Randomised trial of interferon R2b plus ribavirin for 48 weeks or for
24 weeks versus interferon R2b plus placebo for 48 weeks for treatment
of chronic infection with hepatitis C virus. Lancet 1998, 352, 1426–
1432.
(5) Choo, Q. L.; Kuo, G.; Weiner, A. G.; Overby, L. R.; Bradley, D. W.;
Houghton, M. Isolation of a cDNA clone derived from a blood-borne
non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362.
(6) Lindenbach, B. D.; Rice, C. M. Unraveling hepatitis C virus replication
from genome to function. Nature 2005, 436, 933–938.
(7) Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H.
Nonstructural protein 3 of the hepatitis C virus encodes a serine-type
proteinase required for cleavage at the NS3/4 and NS4/5 junctions.
J. Virol. 1993, 67, 3835–3844.
(8) (a) Goudreau, N.; Llina`s-Brunet, M. The therapeutic potential of NS3
protease inhibitors in HCV infection. Expert Opin. InVest. Drugs 2005,
14, 1129–1144. (b) Manns, M. P.; Foster, G. R.; Rockstroh, J. K.;
Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV
treatmentsfinding the right path. Nat. ReV. Drug DiscoVery 2007, 6,
991–1000. (c) Sheldon, J.; Barreiro, P.; Soriano, V. Novel protease
and polymerase inhibitors for the treatment of hepatitis C virus
infection. Expert Opin. InVest. Drugs 2007, 16, 1171–1181.
(9) Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen,
K.; Jao, E.; Liu, Y-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.;
Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.;
Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.;
Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo,
P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.;
Prongay, A.; Madision, Broske, L.; Cui, X.; Cheng, K-C.; Hsieh, T. Y.;
Brisson, J-M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogonowich-
Knipp, S.; Pavlovsky, A.; Prudence, B.; Saksena, A. K.; Ganguly,
A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of
(1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S)-
[[[(1,1-dimethylethyl)-amino]carbonyl]amio]-3,3-dimethyl-1-oxobutyl]-
6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034),
a selective, potent, orally bioavailable, hepatitis C virus NS3 protease
inhibitor: a potential therapeutic agent for the treatment of hepatitis C
infection. J. Med. Chem. 2006, 49, 6074–6086.
(10) Schering-Plough Press Release Aug 4th, 2008: Top-Line Results of
Boceprevir Phase II Study Showed High Rate of Sustained Response
(SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients; Schering-
Plough: Kenilworth, NJ, 2008. Schering-Plough Web site: http://
(11) (a) Yip, Y.; Victor, F.; Lamar, J.; Johnson, R.; Wang, Q. M.; Glass,
J. I.; Yumibe, N.; Wakulchik, M.; Munroe, J.; Chen, S.-H. P4 and
P1′ optimization of bicycloproline P2 bearing tetrapeptidyl R-keto-
amides as HCV protease inhibitors. Bioorg. Med. Chem. Lett. 2004,
14, 5007–5011. (b) Chen, S.-H.; Lamar, J.; Yip, Y.; Victor, F.;
Johnson, R. B.; Wang, Q. M.; Glass, J. I.; Heinz, B.; Colacino, J.;
Guo, D.; Tebbe, M.; Munroe, J. E. P1 and P1′ optimization of [3,4]-
bicycloproline P2 incorporated tetrapeptidyl R-ketoamide based HCV
protease inhibitors. Lett. Drug Des. DiscoVery 2005, 2, 118–123. (c)
(16) (a) Venkatraman, S.; Wu, W.; Prongay, A.; Girijavallabhan, V.;
Njoroge, F. G. Potent inhibitors of HCV-NS3 protease derived from
boronic acids. Bioorg. Med. Chem. Lett. 2008, doi: 10.1016/j.bmcl.
2008.10.124. (b) Bennett, J. M.; Campbell, A. D.; Campbell, A. J.;
Carr, M. G.; Dunsdon, R. M.; Greening, J. R.; Hurst, D. N.; Jennings,
N. S.; Jones, P. S.; Jordan, S.; Kay, P. B.; O’Brien, M. A.; King-
Underwood, J.; Raynham, T. M.; Wilkinson, C. S.; Wilkinson, T. C. I.;
Wilson, F. X. The identification of R-ketoamides as potent inhibitors
of hepatitis C virus NS3-4A proteinase. Bioorg. Med. Chem. Lett. 2001,
11, 355–357. (c) Han, W.; Hu, Z.; Jiang, X.; Decicco, C. P.
R-Ketoamides, R-ketoesters and R-diketones as HCV NS3 protease
inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 711–713.
(17) Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.;
Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric
assay for the hepatitis C virus serine protease. Anal. Biochem. 1999,
270, 268–275.
(18) Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.;
Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs
in a hepatoma cell line. Science 1999, 285, 110–113.